James MacPherson MBA
Executive Director
James is Managing Director of CJ3 Capital, and brings extensive experience and expertise managing direct investments from origination to commercialisation.
Having held operational positions, CEO roles, and board positions across a diverse range of industries including agriculture and health related assets, James will focus on Microbio’s strategic direction, business processes, and governance structures to drive sustainable company growth.
Dr Flavia Huygens PhD
Executive Director, Founder and Chief Scientific Officer
Flavia’s 30-year teaching and research career has been focused on molecular microbiology, with a particular focus on human pathogens.
Flavia’s expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics has culminated in the creation of InfectID, a diagnostic test that identifies bacterial, fungal and viral pathogens.
Matt McNamara MBA GAICD
Director
Matt is passionate about commercialising promising human healthcare technologies. Matt continues to invest in and commercialise great healthcare technologies through an exciting portfolio of executive/non-executive board and advisory roles.
Matt has more than 30 years of experience in the healthcare and medical sciences sector, including more than 20 years as a venture capitalist; 14 years as CIO at BioScience Managers (4 funds. >$200M FUM. >20% IRR) Prior to this Matt was CEO of SciCapital pre-seed fund and also served as SVP Business Development for eBioinformatics Inc. Initially, Matt spent over a decade in the pharma industry working in Sales & Marketing with Merck & Co. and in General Management at Johnson and Johnson Medical Pty Ltd.
Matt has a BSc (Hons) in Molecular Biology, an MBA, and is a GAICD.
Colin Keating
Chief Executive Officer
Colin is a highly skilled executive leader, with more than 25 years’ experience across various industries and global regions, leading both publicly listed entities and privately held businesses. With a focus on people and culture, Colin has a demonstrable track record of establishing, developing, and nurturing high performing teams that have consistently delivered on both customer and organisational objectives.
Colin’s recent experience includes the Interim CEO role at MindBio Therapeutics, where he was responsible for building the business to enable sustainable growth post-listing on the Canadian Stock Exchange. This included creating a strategy to facilitate revenue generation and growth capability in the short and medium term; diversifying revenue generation capability and ‘de-risking’ the investment strategy.